









Markets
/
Stocks
/
nasdaq-hcwb
/

HCW Biologics Inc

HCWB

4.230USD

-0.310-6.83%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

9.08MMarket Cap

LossP/E TTM



HCW Biologics Inc

4.230

-0.310-6.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

182 / 506

Overall Ranking

297 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

35.000

Target Price

+670.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.57M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 101.49.

Overvalued

The company’s latest PE is -0.13, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 613.16K shares, increasing 11.43% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.68.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.37, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 6.55K, representing a year-over-year decrease of 98.94%, while its net profit experienced a year-over-year decrease of 20.93%.

Score

Industry at a Glance

Previous score

5.37

Change



Financials

3.90

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.35

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.76

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.14, which is 5.55% below the recent high of -0.15 and -11101.08% above the recent low of -15.54.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 182/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for HCW Biologics Inc is 35.00, with a high of 35.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

35.000

Target Price

+670.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

HCW Biologics Inc

HCWB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.23, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 6.84 and the support level at 2.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.23

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

47.930

Neutral

STOCH(KDJ)(9,3,3)

38.169

Neutral

ATR(14)

0.645

High Vlolatility

CCI(14)

-10.338

Neutral

Williams %R

65.708

Sell

TRIX(12,20)

-0.194

Sell

StochRSI(14)

10.726

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.426

Sell

MA10

4.175

Buy

MA20

4.654

Sell

MA50

4.435

Sell

MA100

5.374

Sell

MA200

9.628

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 31.10%, representing a quarter-over-quarter decrease of 27.43%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Wong (Hing C)

509.96K

+27.06%

Byam (Rebecca)

43.01K

+24.49%

Garrett (Scott T)

25.50K

+280.84%

Flowers (Lee)

5.72K

+20.23%

Winer (Gary M)

4.08K

+858.82%

Greene (Rick Scott)

2.07K

+87.14%

Rhode (Peter)

1.94K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.95, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.